REGN

Regeneron Pharmaceuticals Inc

973.36

USD

+12.10

+1.26%

Nov 03, 16:00 UTC -5

Closed

Pre-Market

979.50

+6.14

+0.63%

Regeneron Pharmaceuticals Inc (REGN) Earnings

REGN Earnings Reports

Positive Surprise Ratio

REGN beat 36 of 43 last estimates.

84%

Next Report

Date of Next Report

Jan 28, 2027

Estimate for Q4 26 (Revenue/ EPS)

$5.78B

$23.78

Implied change from Q3 26 (Revenue/ EPS)

+13.04%

+18.49%

Implied change from Q4 25 (Revenue/ EPS)

+48.88%

+107.87%

Regeneron Pharmaceuticals Inc earnings per share and revenue

On Oct 30, 2026, REGN reported earnings of 20.07 USD per share (EPS) for Q3 26, beating the estimate of 16.56 USD, resulting in a 21.18% surprise. Revenue reached 5.12 billion, compared to an expected 4.65 billion, with a 10.07% difference. The market reacted with a +13.33% price change (close before vs. close after earnings).

Looking ahead to Q4 26, -- analysts forecast an EPS of 23.78 USD, with revenue projected to reach 5.78 billion USD, implying an increase of 18.49% EPS, and increase of 13.04% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

BioNTech SE - ADR

Report Date

Nov 03, 2026 For Q3 26

Estimate

$0.80

Actual

$1.81

Surprise

+126.53%

Amgen Inc

Report Date

Nov 03, 2026 For Q3 26

Estimate

$5.90

Actual

$6.45

Surprise

+9.16%

Rhythm Pharmaceuticals, Inc. Common Stock

Report Date

Nov 03, 2026 For Q3 26

Estimate

-$0.72

Actual

-$0.61

Surprise

+15.83%

Mirum Pharmaceuticals, Inc. Common Stock

Report Date

Nov 03, 2026 For Q3 26

Estimate

-$0.49

Actual

-$0.87

Surprise

-75.30%

Tarsus Pharmaceuticals, Inc. Common Stock

Report Date

Nov 03, 2026 For Q3 26

Estimate

-$2.78

Actual

-$0.78

Surprise

+72.00%

Denali Therapeutics Inc. Common Stock

Report Date

Nov 03, 2026 For Q3 26

Estimate

-$0.54

Actual

-$0.64

Surprise

-17.95%

Alamar Biosciences, Inc. Common Stock

Report Date

Nov 03, 2026 For Q3 26

Estimate

-$0.21

Actual

-$0.19

Surprise

+12.96%

Ultragenyx Pharmaceutical Inc.

Report Date

Nov 03, 2026 For Q3 26

Estimate

-$1.13

Actual

-$1.15

Surprise

-1.83%

Arvinas, Inc

Report Date

Nov 03, 2026 For Q3 26

Estimate

-$0.88

Actual

-$0.82

Surprise

+7.71%

Oculis Holding AG Ordinary shares

Report Date

Nov 03, 2026 For Q3 26

Estimate

-$0.42

Actual

-$0.30

Surprise

+28.03%

FAQ

What were Regeneron Pharmaceuticals Inc's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Regeneron Pharmaceuticals Inc reported EPS of $20.07, beating estimates by 21.18%, and revenue of $5.12B, 10.07% above expectations.

How did the market react to Regeneron Pharmaceuticals Inc's Q3 2026 earnings?

The stock price moved up 13.33%, changed from $818.77 before the earnings release to $927.89 the day after.

When is Regeneron Pharmaceuticals Inc expected to report next?

The next earning report is scheduled for Jan 28, 2027.

What are the forecasts for Regeneron Pharmaceuticals Inc's next earnings report?

Based on -- analysts, Regeneron Pharmaceuticals Inc is expected to report EPS of $23.78 and revenue of $5.78B for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.